FDA panel loosens restrictions for controversial peptides popular online
A US FDA advisory panel has voted to loosen restrictions on the production of certain controversial peptides, such as BPC-157 and TB-500. These substances have gained popularity in online wellness communities for unproven health and performance benefits, despite warnings from health experts regarding their safety.
Why it matters
The decision highlights the tension between the growing 'biohacking' trend and the regulatory oversight required to ensure public safety for unproven medical treatments.
Image source, Getty Images By Madeline Halpert and Kathryn Armstrong Published 23 July 2026 A US Food and Drug Administration (FDA) advisory panel has voted to loosen restrictions on controversial peptides that have become popular online, but have not been well researched for human usage.
The panel narrowly voted to allow specialised pharmacies to produce drugs including BPC-157, TB-500 and KPV, a major regulatory hurdle towards making them available via prescription.
Peptides are small proteins that our bodies normally produce and that have long been used to treat medical conditions, including diabetes.
But unregulated injectable peptides have exploded in the online wellness community - including among many young influencers - since GLP-1s (weight loss drugs) became mainstream.
The FDA does not have to follow the panel's recommendations, but often does.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in